A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

Bio2RDF identifier

NCT01073293

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01073293

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01073293

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

1,054

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

This study will evaluat ...... owing the first dose of V503.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study of V503 Vaccine Given ...... 11 to 15 Year Olds (V503-007)

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT01073293 [clinicaltrials_resource:36baf97db786b77a36f89d68df8f96bb]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:3684911837072c203f7ffbd1a1630dae]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:3bfa5831ba6639d2112d73384960d953]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:8b38efc55759ebc369f4d98b7b0f9d45]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:9c215418041e836622987e7bf74614dd]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:a3b2427819557a82734f46c373e610a3]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:b0bc0e4e6bca11ece98f23e78c68a960]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:f780b067eaf37cb553db4e1549ec2979]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:fe37a3a61fb2c2cbb57a924baa7143cc]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 4 weeks following Month 6 vaccination [clinicaltrials_resource:702c9a27d975f0713b8363190f85e27b]

completion date [clinicaltrials_vocabulary:completion-date]

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Papillomavirus Infections [clinicaltrials_resource:e7646d8a181124843a18745b0c590f29]

condition browse [clinicaltrials_vocabulary:condition-browse]

Papillomavirus Infections [clinicaltrials_resource:e7646d8a181124843a18745b0c590f29]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Papillomavirus Infections [clinicaltrials_resource:e7646d8a181124843a18745b0c590f29]

country [clinicaltrials_vocabulary:country]

Austria [clinicaltrials_resource:9891739094756d2605946c867b32ad28]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01073293 [clinicaltrials_resource:2951a590e6f8ffd53afc3d6e427392da]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2014-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

REPEVAX™ (Non-concomitant) [clinicaltrials_resource:35af64dee4fba6d3b5ec0179bfdae9f1]

REPEVAX™ (Concomitant) [clinicaltrials_resource:ccd3e2d425994396ee2e0a432ba83ab4]

V503 Vaccine [clinicaltrials_resource:e5798ba6562b18a99f2cd9719f8cba4b]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01073293

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase III Open-Label Clinica ...... olescents (11 to 15 Year Olds)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

V503-007

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 [clinicaltrials_resource:NCT01073293/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Medical Director [clinicaltrials_resource:40a67f92689cc2448e30b55e26eaccf7]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Belgium: Federal Agency for Medicines and Health Products, FAMHP [clinicaltrials_resource:04a14412f61b7c7b4f18f34f0e37da3f]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT01073293 [clinicaltrials_resource:f3c119f8afc8599a8df3f0cf031ee4f3]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT01073293 [clinicaltrials_resource:ff259485b610acc775ca45de58cb1609]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2010_512

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

start date [clinicaltrials_vocabulary:start-date]

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01073293 study design [clinicaltrials_resource:f18104fbaf7a2d6a9209004fa53cb779]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01073293

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01073293

http://www.w3.org/2001/XMLSchema#string

title

A Study of V503 Vaccine Given ...... 11 to 15 Year Olds (V503-007)

@en